scholarly journals Investigation on Intervention Effects of Applying Proton Pump Inhibitors in Inpatients

2019 ◽  
Author(s):  
Guotong Qing ◽  
Jian Wu ◽  
Runfong Wei ◽  
Di Wu ◽  
Yipping Gou ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Age Distribution ◽  
Information Management System ◽  
Hospitalized Patients ◽  
Utilization Rate ◽  
Coincidence Rate ◽  
Cross Sectional ◽  
Clinical Pharmacists ◽  
Before And After

Abstract Background. To investigate the intervention effect of clinical pharmacists on irrational use of proton pump inhibitors (PPIs) in clinicians. Methods. A cross-sectional study was used to through the hospital information management system survey, before intervention (July 15th, 2016, Aug 15th, 2016 and Sep 15th 2016) and dry prognosis (July 15th, 2017, Aug 15th, 2017 and Sep 15th, 2017) all the use of PPIs inpatients related information. According to the guidelines of "drug instructions" and "experts on stress ulcer prevention and treatment experts", the standard of drug use was formulated, and the use of PPIs before and after intervention was evaluated and analyzed in accordance with the standard, and the results of intervention were evaluated. Results. The total number of hospitalized patients surveyed before the intervention was 1,693, the average utilization rate of proton pump inhibitors was 27.05% and the coincidence rate was 52.40%. The total number of hospitalized patients investigated after the intervention was 2,095, the average utilization rate of proton pump inhibitors was 8.54%, and the coincidence rate was 68.16%. Before and after the intervention, there was no difference in gender ratio and age distribution, the decrease of the utilization rate and the improvements of the qualified rate after intervention were statistically significant.Conclusion. According to the standards of PPIs, clinical pharmacists strictly implement the special prescription review system and other intervention measures, which can significantly improve the level of PPIs rational clinical medication.

scholarly journals Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Simone Janett ◽  
Pietro Camozzi ◽  
Gabriëlla G. A. M. Peeters ◽  
Sebastiano A. G. Lava ◽  
Giacomo D. Simonetti ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Treatment ◽  
Cross Sectional ◽  
Magnesium Metabolism ◽  
Poor Renal Function ◽  
Long Term Treatment

In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with another but not with a histamine type-2 receptor antagonist. The association between proton-pump inhibitors and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them: 6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship between magnesium metabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.

scholarly journals The use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational study

2018 ◽  
Vol 26 (7) ◽  
pp. 1012-1021
Author(s):  
Hadiah AlMutairi ◽  
Máire O'Dwyer ◽  
Mary McCarron ◽  
Philip McCallion ◽  
Martin C. Henman
Keyword(s):  
Older Adults ◽  
Intellectual Disability ◽  
Observational Study ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cross Sectional

scholarly journals Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia

2021 ◽  
Vol 22 (24) ◽  
pp. 13609
Author(s):  
Lucas Wauters ◽  
Raúl Y. Tito ◽  
Matthias Ceulemans ◽  
Maarten Lambaerts ◽  
Alison Accarie ◽  
...  
Keyword(s):  
Functional Dyspepsia ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Potential Role ◽  
Short Term ◽  
Beneficial Effects ◽  
Rrna Sequencing ◽  
Before And After

Proton pump inhibitors (PPI) may improve symptoms in functional dyspepsia (FD) through duodenal eosinophil-reducing effects. However, the contribution of the microbiome to FD symptoms and its interaction with PPI remains elusive. Aseptic duodenal brushings and biopsies were performed before and after PPI intake (4 weeks Pantoprazole 40 mg daily, FD-starters and controls) or withdrawal (2 months, FD-stoppers) for 16S-rRNA sequencing. Between- and within-group changes in genera or diversity and associations with symptoms or duodenal factors were analyzed. In total, 30 controls, 28 FD-starters and 19 FD-stoppers were followed. Mucus-associated Porphyromonas was lower in FD-starters vs. controls and correlated with symptoms in FD and duodenal eosinophils in both groups, while Streptococcus correlated with eosinophils in controls. Although clinical and eosinophil-reducing effects of PPI therapy were unrelated to microbiota changes in FD-starters, increased Streptococcus was associated with duodenal PPI effects in controls and remained higher despite withdrawal of long-term PPI therapy in FD-stoppers. Thus, duodenal microbiome analysis demonstrated differential mucus-associated genera, with a potential role of Porphyromonas in FD pathophysiology. While beneficial effects of short-term PPI therapy were not associated with microbial changes in FD-starters, increased Streptococcus and its association with PPIeffects in controls suggest a role for duodenal dysbiosis after long-term PPI therapy.

Prevalence and Associations of the Use of Proton-Pump Inhibitors in Nursing Homes: A Cross-Sectional Study

2013 ◽  
Vol 14 (4) ◽  
pp. 265-269 ◽  
Author(s):  
Philipe de Souto Barreto ◽  
Maryse Lapeyre-Mestre ◽  
Céline Mathieu ◽  
Christine Piau ◽  
Catherine Bouget ◽  
...  
Keyword(s):  
Nursing Homes ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional

scholarly journals Association between the Use of Proton Pump Inhibitors and Cognitive Impairment in Older Adults

2018 ◽  
Vol 60 (1) ◽  
Author(s):  
Camilo Gómez ◽  
Miguel German Borda Borda ◽  
Mario Ulises Pérez ◽  
Pamela Tella Vega ◽  
Carlos Alberto Cano Gutiérrez
Keyword(s):  
Older Adults ◽  
Cognitive Impairment ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Adult Population ◽  
Cross Sectional ◽  
Adjusted Risk ◽  
Risk Increase ◽  
Older Adult Population ◽  
State Examination

Objective: The objective was to describe the association between the presence of cognitive impairment and the use of proton pump inhibitors (PPI) in the older adult population in Bogotá, Colombia. Methods: We analyzed the SABE Bogotá study. This study included 2,000 people over 60 years, in a cross-sectional sample. The variable of interest was the alteration in the modified Mini-Mental State Examination (MMSE-M). It was related to the use of PPI. This analysis was adjusted for factors such as sex, age, years of schooling and marital status. Results: The average age was 71.17±8.05 years, 63.4% were women. We found that 20.7% used PPIs, with an average duration of use of 74.8±93.76 months. 12.6% of older adults had altered MMSE-M, with a higher prevalence in PPI users (25.4% vs. 20.02%; p: 0.049). In the multivariate analysis, an association of adjusted risk increase was found between cognitive impairment and the use of PPIs for ≥24 months (OR: 1.90; CI: 1.11-3.24; p = 0.018). Conclusions: This study shows an association of a significant increase in the risk between using PPIs for ≥ 24 months and developing cognitive impairment. More studies are needed to conclude a direct causality relationship.

scholarly journals The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy

2020 ◽  
Vol 9 (11) ◽  
pp. 3728
Author(s):  
Jordan Guillot ◽  
Sandy Maumus-Robert ◽  
Alexandre Marceron ◽  
Pernelle Noize ◽  
Antoine Pariente ◽  
...  
Keyword(s):  
Older Adults ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cross Sectional Study ◽  
Potentially Inappropriate Medications ◽  
Middle Aged ◽  
Cross Sectional ◽  
Long Acting ◽  
Chronic Use ◽  
Inappropriate Medications

We aimed to describe the burden represented by potentially inappropriate medications (PIMs) in chronic polypharmacy in France. We conducted a nationwide cross-sectional study using data from the French National Insurance databases. The study period was from 1 January 2016 to 31 December 2016. Chronic drug use was defined as uninterrupted daily use lasting ≥6 months. Chronic polypharmacy was defined as the chronic use of ≥5 medications, and chronic hyperpolypharmacy as the chronic use of ≥10 medications. For individuals aged ≥65 (older adults), PIMs were defined according to the Beers and Laroche lists, and for individuals aged 45–64 years (middle-aged) PIMs were defined according to the PROMPT (Prescribing Optimally in Middle-aged People’s Treatments) list. Among individuals with chronic polypharmacy, 4009 (46.2%) middle-aged and 18,036 (64.8%) older adults had at least one chronic PIM. Among individuals with chronic hyperpolypharmacy, these figures were, respectively, 570 (75.0%) and 2544 (88.7%). The most frequent chronic PIM were proton pump inhibitors (43.4% of older adults with chronic polypharmacy), short-acting benzodiazepines (older adults: 13.7%; middle-aged: 16.1%), hypnotics (6.1%; 7.4%), and long-acting sulfonylureas (3.9%; 12.3%). The burden of chronic PIM appeared to be very high in our study, concerning almost half of middle-aged adults and two-thirds of older adults with chronic polypharmacy. Deprescribing interventions in polypharmacy should primarily target proton pump inhibitors and hypnotics.

Sign in / Sign up

Export Citation Format

Share Document